TRACER (S1415CD) NEWSLETTER









January 2018

STUDY UPDATES

- ★ As of 01/22/18, there are 1,316 patients registered across 42 components (12 out of 13 Cohort components, 7 out of 8 Usual Care components, 11 out of 12 Intervention Arm 3 components, and 12 out of 12 Intervention Arm 4 components).
- → As of 01/05/18, **ALL of our intervention components** have completed their order change process and are open for enrollment.

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

CONGRATULATIONS AND THANK YOU TO OUR TOP ACCRUERS

These sites have reached at least 75% of their overall accrual:

- **★** Illinois Cancer Care in Peoria, IL
- ★ St. Luke's Mountain States Tumor Institute in Boise, ID
- **★** Cancer Care Specialists of Central Illinois in Decatur, IL

Congratulations to the Cancer Center of Kansas and Greenville Memorial Hospital for completing 100% of their enrollment!


ACCRUAL GOALS

TrACER is reliant on each component meeting its accrual goal by the funder's deadline of March 31, 2019. If you are facing challenges to reaching your accrual goal (99 patients RCT arms, 60 patients cohort arm), please contact the TrACER team ASAP to help problem solve.

Over the next few months, the HICOR team will send individual reports to each site to show your accrual by component relative to the overall study accrual goal. Please see the graphics on **page 2** for an overview of accrual.

Contact Us

TrACER Total Accrual as of January 22, 2018



TrACER Accrual in the Past 12 Months

